^
Association details:
Biomarker:DLL3 overexpression
Cancer:Small Cell Lung Cancer
Drug Class:PD-L1 inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer

Published date:
09/20/2023
Excerpt:
In the ES-SCLC cohort (n = 30), the progression-free survival associated with PE plus anti-PD-L1 antibody was significantly worse in DLL3High cases than in DLL3Low cases (4.7 vs. 7.4 months, P = 0.01).
Secondary therapy:
etoposide oral
DOI:
https://doi.org/10.1038/s41416-023-02427-3
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Tumor microenvironment-mediated immune profiles and efficacy of platinum doublet chemotherapy plus ICIs stratified by DLL3 expression in small cell lung cancer.

Published date:
05/25/2023
Excerpt:
In ES-SCLC cohort (n = 17), the PFS of PE plus anti-PD-L1 antibody in patients with DLL3High was significantly worse than those in patients with DLL3Low (4.1 months [95% CI, 2.0-6.3] vs. 7.4 months [95% CI, 2.5-12.3]; HR 3.78 [95% CI, 1.1-12.5], p = 0.03).
Secondary therapy:
Chemotherapy + etoposide oral
DOI:
10.1200/JCO.2023.41.16_suppl.8586